Five-year overall survival by era. (A) Kaplan-Meier estimates of OS... | Download Scientific Diagram
![Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram](https://www.researchgate.net/publication/333780703/figure/fig1/AS:769686505541634@1560518971977/Kaplan-Meier-survival-curves-comparing-5-year-overall-survival-OS-and-recurrence-free.png)
Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram
![5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/96376398-fbed-4daa-bd31-dd6b9854d8fc/gr3.jpg)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
![Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer](https://www.mdpi.com/cancers/cancers-11-01239/article_deploy/html/images/cancers-11-01239-g006.png)
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
![Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2019/jco.2019.37.issue-28/jco.19.00934/20190919/images/large/jco.19.00934t2.jpeg)
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology
![Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10120-017-0716-7/MediaObjects/10120_2017_716_Fig3_HTML.gif)
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink
![Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-85223-4/MediaObjects/41598_2021_85223_Fig1_HTML.png)
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports
![Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-018-0155-7/MediaObjects/41408_2018_155_Fig1_HTML.png)
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal
![5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/3ff708fc-ff94-456b-b4b1-40e9cd97d4eb/gr1.gif)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
![5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO 5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO](https://www.bjmo.be/app/uploads/2021/11/Banner-KN024-OS-Curve-2400x1800-NOV21_uitsnede-1-1024x464.jpg)
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
![Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/328286526/figure/fig2/AS:682002189660161@1539613401325/Overall-survival-curve-by-treatment-method-The-5-year-overall-survival-rate-and-median.png)
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
![P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Journal of Thoracic Oncology P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/9545bc75-143d-4d88-964c-180f01ca18fa/fx1.jpg)
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Journal of Thoracic Oncology
![4baseCare on Twitter: 4baseCare on Twitter:](https://pbs.twimg.com/media/FPpvkhUaIAAqXds.jpg)